Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline

Management provides pipeline update for assets including its COVID-19 vaccine and peptide therapeutic   New York, NY –  June 03, 2020 — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today is providing an update on its pipeline of therapeutics including six compounds in various stages of clinical development, targeting atopic dermatitis, lupus as well as a COVID-19 […]

Hoth Therapeutics Initiates Preclinical Study Including Topical Form of Aprepitant for Dermatological Treatment Relating to Side Effects of Cancer Medication

New York, NY – November 14, 2019 – Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced, in partnership with the George Washington University (GW), the initiation of a preclinical study of […]

Hoth Therapeutics Initiates Confirmatory Study for Lupus Treatment

New York, NY – November. 6, 2019  – Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced initiating a Phase 1 confirmatory study, related to their proprietary […]

Hoth Therapeutics, Inc. Announces Positive Results From Pilot Study of BioLexa on Diabetic Skin Ulcers

New York, NY – July 22, 2019 – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced initial results of its Pilot Study of BioLexa application on diabetic skin […]

Hoth Therapeutics Enters into Sponsored Research Agreement with Renowned George Washington University

Company analyzing efficacy of Aprepitant, in reducing skin-related disorders attributed to cancer treatment   New York, NY –  June 28, 2019 – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that […]

Hoth Therapeutics Forms Wholly Owned Australian Subsidiary, in Preparation of Upcoming Clinical Trials for Atopic Dermatitis Solution

New York, NY – June 11, 2019 – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as eczema-as well as dermatological and chronic wound disorders, announced the formation of its subsidiary, Hoth Therapeutics Australia Pty Ltd, in anticipation to perform […]

Hoth Therapeutics to Begin Production of BioLexa Therapeutic for Upcoming Toxicology and Clinical Trials

New York, NY – June 10, 2019 – Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as eczema-as well as dermatological and chronic wound disorders, today announced it has signed contracts with providers for production of their BioLexa therapeutic, in preparation […]

Hoth Therapeutics Signs Term Sheet with Zylö Therapeutics to Acquire a License and Jointly Develop a Product to Treat Lupus

Hoth and Zylö to use new topical application of an endocannabinoid, anandamide (AEA), in nanoparticles   New York, NY –  May 14, 2019 – Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound […]